Who
Lori Freedman
Chief Admin. and Legal Officer
Company insider
Files Form 4 as: Chief Admin. and Legal Officer, Organogenesis Holdings; VP Corp. Affairs, GC and Sec, EyePoint.
In numbers
- Trades disclosed
- 77
- Buys
- 3
- Sells
- 5
- Bought
- $726K
- Sold
- $93K
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 18 Oct 2007
- Last trade
- 18 Feb 2026
- Last filed
- 3 Mar 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 18 Feb 2026filed 3 Mar 2026 | ORGO Organogenesis HoldingsBiotechnology | SEC FORM 4 Code A | —43,212 at $0.00 | filing |
| 18 Feb 2026filed 3 Mar 2026 | ORGO Organogenesis HoldingsBiotechnology | SEC FORM 4 Code F | $55K14,411 at $3.84 | filing |
| 18 Feb 2026filed 3 Mar 2026 | ORGO Organogenesis HoldingsBiotechnology | SEC FORM 4 Code A | —43,212 at $0.00 | filing |
| 18 Feb 2026filed 3 Mar 2026 | ORGO Organogenesis HoldingsBiotechnology | SEC FORM 4 Code F | $55K14,411 at $3.84 | filing |
| 18 Feb 2026filed 20 Feb 2026 | ORGO Organogenesis HoldingsBiotechnology | SEC FORM 4 Code A | —203,125 at $0.00 | filing |
| 18 Feb 2026filed 20 Feb 2026 | ORGO Organogenesis HoldingsBiotechnology | SEC FORM 4 Code A | —42,780 at $0.00 | filing |
| 18 Feb 2026filed 20 Feb 2026 | ORGO Organogenesis HoldingsBiotechnology | SEC FORM 4 Code F | $55K14,267 at $3.84 | filing |
| 18 Feb 2026filed 20 Feb 2026 | ORGO Organogenesis Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —115,812 at $0.00 | filing |
| 18 Feb 2026filed 20 Feb 2026 | ORGO Organogenesis Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —115,812 at $0.00 | filing |
| 18 Feb 2026filed 20 Feb 2026 | ORGO Organogenesis HoldingsBiotechnology | SEC FORM 4 Code A | —203,125 at $0.00 | filing |
| 18 Feb 2026filed 20 Feb 2026 | ORGO Organogenesis HoldingsBiotechnology | SEC FORM 4 Code A | —42,780 at $0.00 | filing |
| 18 Feb 2026filed 20 Feb 2026 | ORGO Organogenesis HoldingsBiotechnology | SEC FORM 4 Code F | $55K14,267 at $3.84 | filing |
| 15 Feb 2026filed 18 Feb 2026 | ORGO Organogenesis HoldingsBiotechnology | SEC FORM 4 Code F | $15K4,043 at $3.73 | filing |
| 15 Feb 2026filed 18 Feb 2026 | ORGO Organogenesis HoldingsBiotechnology | SEC FORM 4 Code F | $91K24,428 at $3.73 | filing |
| 15 Feb 2026filed 18 Feb 2026 | ORGO Organogenesis HoldingsBiotechnology | SEC FORM 4 Code F | $48K12,761 at $3.73 | filing |
| 15 Feb 2026filed 18 Feb 2026 | ORGO Organogenesis HoldingsBiotechnology | SEC FORM 4 Code F | $50K13,510 at $3.73 | filing |
| 15 Feb 2026filed 18 Feb 2026 | ORGO Organogenesis HoldingsBiotechnology | SEC FORM 4 Code F | $15K4,043 at $3.73 | filing |
| 15 Feb 2026filed 18 Feb 2026 | ORGO Organogenesis HoldingsBiotechnology | SEC FORM 4 Code F | $91K24,428 at $3.73 | filing |
| 15 Feb 2026filed 18 Feb 2026 | ORGO Organogenesis HoldingsBiotechnology | SEC FORM 4 Code F | $48K12,761 at $3.73 | filing |
| 15 Feb 2026filed 18 Feb 2026 | ORGO Organogenesis HoldingsBiotechnology | SEC FORM 4 Code F | $50K13,510 at $3.73 | filing |
News
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Downgraded by Jefferies Financial Group to "Hold"EYPT · tickerreport.com · 19 Oct 2026Critical Review: Eyepoint Pharmaceuticals (NASDAQ:EYPT) and GSK (NYSE:GSK)EYPT · themarketsdaily.com · 11 Oct 2026
0 headlines in the last 90 days name Lori Freedman; 2 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.